Private Advisor Group LLC Acquires 525 Shares of Danaher Corporation (DHR)
Private Advisor Group LLC increased its position in shares of Danaher Corporation (NYSE:DHR) by 3.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,946 shares of the conglomerate’s stock after buying an additional 525 shares during the period. Private Advisor Group LLC’s holdings in Danaher Corporation were worth $1,539,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in DHR. Parnassus Investments CA raised its position in shares of Danaher Corporation by 15.3% in the first quarter. Parnassus Investments CA now owns 8,622,528 shares of the conglomerate’s stock worth $712,738,000 after buying an additional 1,143,284 shares during the period. Bank of New York Mellon Corp raised its position in shares of Danaher Corporation by 0.7% in the first quarter. Bank of New York Mellon Corp now owns 7,645,818 shares of the conglomerate’s stock worth $653,946,000 after buying an additional 50,673 shares during the period. Norges Bank bought a new position in shares of Danaher Corporation during the fourth quarter worth approximately $465,363,000. Dodge & Cox bought a new position in shares of Danaher Corporation during the fourth quarter worth approximately $406,424,000. Finally, Flossbach Von Storch AG raised its position in shares of Danaher Corporation by 6.2% in the first quarter. Flossbach Von Storch AG now owns 3,996,209 shares of the conglomerate’s stock worth $341,796,000 after buying an additional 234,770 shares during the period. Institutional investors and hedge funds own 76.22% of the company’s stock.
Shares of Danaher Corporation (DHR) traded down 0.33% during trading on Friday, reaching $81.01. 2,425,291 shares of the company traded hands. The stock has a market capitalization of $56.28 billion, a PE ratio of 25.86 and a beta of 1.03. The firm’s 50-day moving average is $83.93 and its 200-day moving average is $84.29. Danaher Corporation has a 12-month low of $75.71 and a 12-month high of $88.01.
Danaher Corporation (NYSE:DHR) last released its quarterly earnings results on Thursday, July 20th. The conglomerate reported $0.99 EPS for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.02. Danaher Corporation had a net margin of 12.63% and a return on equity of 11.15%. The business had revenue of $4.51 billion during the quarter, compared to analysts’ expectations of $4.50 billion. During the same quarter in the previous year, the company earned $0.90 EPS. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, equities analysts predict that Danaher Corporation will post $3.95 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, July 28th. Shareholders of record on Friday, June 30th were paid a $0.14 dividend. The ex-dividend date of this dividend was Wednesday, June 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.69%. Danaher Corporation’s dividend payout ratio is presently 17.83%.
COPYRIGHT VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/04/danaher-corporation-dhr-shares-bought-by-private-advisor-group-llc-updated-updated-updated.html.
A number of research analysts recently commented on DHR shares. Zacks Investment Research lowered shares of Danaher Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, July 27th. BTIG Research reiterated a “buy” rating and issued a $92.00 price target on shares of Danaher Corporation in a research note on Sunday, April 23rd. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $88.00 price target (down previously from $89.00) on shares of Danaher Corporation in a research note on Friday, April 21st. BidaskClub upgraded shares of Danaher Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, Citigroup Inc. set a $96.00 target price on shares of Danaher Corporation and gave the stock a “buy” rating in a research report on Friday, July 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $91.76.
In other news, SVP Angela S. Lalor sold 10,815 shares of the company’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $84.16, for a total value of $910,190.40. Following the completion of the sale, the senior vice president now owns 39,020 shares of the company’s stock, valued at approximately $3,283,923.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $81.78, for a total transaction of $799,154.16. Following the sale, the insider now owns 155,520 shares of the company’s stock, valued at $12,718,425.60. The disclosure for this sale can be found here. In the last three months, insiders sold 38,623 shares of company stock valued at $3,206,426. Corporate insiders own 12.20% of the company’s stock.
Danaher Corporation Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.